Autopsy report · NCT04248153

Optimal Timing of BR55 CEUS of the Ovaries

“Sponsor decision; expiration of available study agent due to long recruitment timeline.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 10 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 3 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Bracco Diagnostics, Inc

Sponsor type

Industry

Conditions

Ovarian Cancer

Interventions

BR55

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
  “pending expiration of the supply of study agent.” (72% match in meaning)
• Evaluation of Tissue Oxygen Levels During Breast Reconstruction With a New Surgical Device
  “Sponsor decision to end study.” (71% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (69% match in meaning)
• Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs
  “Study terminated based on decision of Sponsor.” (69% match in meaning)
• A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
  “Sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.